G protein nucleolar 3Genealiases: C77032 · E2IG3 · NNP47 · NS · Nug1
Q-omics provides the consensus-scored GNL3 profile across patient tissues and cancer cell-line models. GNL3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GNL3 is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, GNL3 protein abundance shows 26,351 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRP, and LSCC as cancer lineages where GNL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNL3 survival associations across molecular data types. GNL3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNL3 RNA expression–survival associations across cancer types. High GNL3 expression shows unfavorable associations in ACC, LIHC, KIRC, KIRP and KICH, but favorable associations in READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GNL3 RNA expression.
This table summarizes GNL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GNL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNL3 shows higher tumor expression in KIRP, KIRC, COAD, LIHC, LUAD and STAD. The KIRP box plot shows higher GNL3 RNA expression in tumor versus normal tissue (log2 FC = +1.136, t-test p < 0.001).
This table shows molecular features associated with GNL3 in patient tissues and cancer cell lines. In patient samples, GNL3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GNL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
